<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00750217</url>
  </required_header>
  <id_info>
    <org_study_id>E-54/2007</org_study_id>
    <nct_id>NCT00750217</nct_id>
  </id_info>
  <brief_title>Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches</brief_title>
  <official_title>Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches: A Study on Practicability With Patients Maintained With Daily Dosages Between 60mg and 100mg Methadone.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Psychiatric University Hospital, Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Psychiatric University Hospital, Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Buprenorphine is an important alternative to methadone in the maintenance treatment of heroin
      addiction. Transfer from methadone to buprenorphine requires a reduction of daily methadone
      dosage below 30 mg to avoid withdrawal after the first buprenorphine intake. The study
      hypothesis states that the transfer from a daily methadone dosage between 60 mg and 100 mg to
      buprenorphine can be carried out without withdrawal using buprenorphine patches (35 micro
      grams per hour) within 12 to 48 hours after last methadone intake.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">May 2009</completion_date>
  <primary_completion_date type="Anticipated">February 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Short Opiate Withdrawal Scale</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Heroin use</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Heroin Addiction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine patch and sublingual tablets</intervention_name>
    <description>Buprenorphine patch: 35 micro grams per hour 12 to 48 hours after last methadone intake.
Buprenorphine sublingual tablets: 2mg 48 and 60 hours after last methadone intake; 8mg 72 and 84 hours after last methadone intake; 8mg 96, 102 and 109 hours after last methadone intake.</description>
    <other_name>Transtec (buprenorphine patch)</other_name>
    <other_name>Subutex (buprenorphine sublingual tablets)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age between 18 and 60 years

          -  Methadone maintenance treatment for at least 3 months preceding the study

          -  Daily methadone dosage between 60mg amd 100mg

          -  Sufficient knowledge of German language

          -  Ability to give informed consent

        Exclusion Criteria:

          -  Daily methadone dosage below 60mg amd over 100mg

          -  Prescribed use of benzodiazepines over 30 mg equivalent to diazepam

          -  Misuse or dependence of alcohol and/or GHB/GBL

          -  Pregnant or breast-feeding women

          -  Known intolerance of buprenorphine

          -  Somatic diseases interfering with the study plan
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rudolf Stohler, MD</last_name>
    <role>Study Director</role>
    <affiliation>Psychiatric University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lukas Boesch, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Psychiatirc University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Psychiatric University Hospital</name>
      <address>
        <city>Zurich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melanie Hess, med. pract.</last_name>
      <phone>0041 44 384 21 11</phone>
      <email>melanie.hess@puk.zh.ch</email>
    </contact>
    <contact_backup>
      <last_name>Rudolf Stohler, MD</last_name>
      <phone>0041 44 205 58 00</phone>
      <email>rudolf.stohler@puk.zh.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Melanie Hess, med. pract.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 9, 2008</study_first_submitted>
  <study_first_submitted_qc>September 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2008</study_first_posted>
  <last_update_submitted>September 9, 2008</last_update_submitted>
  <last_update_submitted_qc>September 9, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2008</last_update_posted>
  <responsible_party>
    <name_title>Stohler Rudolf MD</name_title>
    <organization>Psychiatric University Hospital, Zurich</organization>
  </responsible_party>
  <keyword>transfer methadone buprenorphine patch heroin addiction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Behavior, Addictive</mesh_term>
    <mesh_term>Heroin Dependence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
    <mesh_term>Methadone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 23, 2010</submitted>
    <returned>October 19, 2010</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

